Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 21;4(5):807-812.
doi: 10.1002/rth2.12388. eCollection 2020 Jul.

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features

Abraham Z Cheloff  1 , David J Kuter  1 , Hanny Al-Samkari  1
Affiliations

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features

Abraham Z Cheloff et al. Res Pract Thromb Haemost. .

Abstract

Background: Complement may contribute to platelet destruction in immune thrombocytopenia (ITP), but serum complement levels of ITP patients are not well defined. This study characterized C3, C4, and CH50 levels from 108 ITP patients in comparison with 120 healthy subjects.

Methods: Results of complement testing performed using commercially available turbidimetric immunoassays were retrospectively analyzed. Mean complement levels in patients with ITP were compared with levels from a sample of 120 healthy subjects, and subgroups of ITP patients were compared. Regression analyses evaluated for relations between low complement levels and disease severity and response to ITP treatments.

Results: One hundred eight patients with ITP were included. Mean C3, C4, and CH50 were significantly lower in patients with ITP compared with healthy subjects, largely driven by the 32% of patients with ITP with substantial reductions in one or more assays. Patients requiring treatment had lower mean C4 (18.1 vs 23.1 mg/dL; P = .042) and CH50 (50.4 vs 63.0 mg/dL; P = .004). Mean C3 was higher in splenectomized versus nonsplenectomized patients (120.6 vs 101.0 mg/dL; P = .035). In multivariable analyses, reduced complement did not predict treatment response to corticosteroids, intravenous immunoglobulin, or thrombopoietin receptor agonists but low C4 levels did predict more severe ITP (relative to nonsevere disease, odds ratio for severe/refractory disease: 6.28; 95% confidence interval, 0.75-52.54; P = .090). Complement levels in patients with ITP were generally consistent over repeat measurements.

Conclusions: Complement levels are reduced in one-third of patients with ITP and are associated with more severe disease. Additional study is needed to evaluate if hypocomplementemia is predictive of response to emerging complement-directed therapies.

Keywords: blood platelets; complement C3; complement C4; complement hemolytic activity assay; idiopathic; immune thrombocytopenia; purpura; sutimlimab; thrombocytopenic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distributions of C3, C4, and CH50 measurements in patients with ITP (red) versus healthy subjects (green). (A) C3 (nonparametric). (B) C4 (nonparametric). (C) CH50 (parametric). (A) and (B) are interleaved histograms (bin size 15 for A and 5 for B) with results for each group (ITP patients and healthy subjects) paired at each bin to facilitate comparison. Values on the X axis are the center value for a given bin. ITP, immune thrombocytopenia
See this image and copyright information in PMC

References

    1. Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, et al. Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol. 2016;91:995–1001. - PubMed
    1. Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, et al. Autoantibody‐mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88:167–74. - PubMed
    1. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol. 2010;148:638–45. - PMC - PubMed
    1. Kurata Y, Curd JG, Tamerius JD, McMillan R. Platelet‐associated complement in chronic ITP. Br J Haematol. 1985;60:723–33. - PubMed
    1. Broome CM, Roeth A, Kuter DJ, Scully M, Smith R, Wang J, et al. Inhibition of the classical pathway of complement with sutimlimab in chronic immune thrombocytopenic purpura patients without adequate response to two or more prior therapies. Blood. 2019;134:898.